Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. - Wikidata - awgldk - TriplyDB

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q44825022

about

New and emerging disease modifying therapies for multiple sclerosis Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis Pharmacological treatment for memory disorder in multiple sclerosis Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis Natalizumab for relapsing remitting multiple sclerosis Natalizumab for relapsing remitting multiple sclerosis Natalizumab for induction of remission in Crohn's disease Natalizumab for induction of remission in Crohn's disease Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study Natalizumab: A new treatment for relapsing remitting multiple sclerosis Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic Interventions Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes Disease-modifying treatments for multiple sclerosis - a review of approved medications Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis Newer therapies for multiple sclerosis Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Optimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of action Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease Multiple sclerosis-a quiet revolution Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis Shining a light on intestinal traffic Multiple sclerosis Benefits versus risks of latest therapies in multiple sclerosis: a perspective review Review article: anti-adhesion therapies for inflammatory bowel disease Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same?Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis.A herpes simplex virus-derived replicative vector expressing LIF limits experimental demyelinating disease and modulates autoimmunity Review of daclizumab and its therapeutic potential in the treatment of relapsing-remitting multiple sclerosis Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis Multiple sclerosis--new treatment modalities Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab No quiet surrender: molecular guardians in multiple sclerosis brain

P2860

Q22242305-2EFAE765-191A-4E73-9475-124FDD9D334E Q24187126-541F2F1E-9683-4783-9B74-E3D5D4B3B279 Q24201735-CDD9B443-2561-4B9A-87FB-07D8A587222B Q24202108-53452FD1-46D5-4925-B031-7186E8E1F06B Q24235861-8E98986A-FAB7-4B82-8433-5499065736AC Q24241982-A52BC9C7-E389-4F4C-B69C-134610C75C2F Q24245190-779EC2E5-7CB4-4346-AF34-F92F60FC62EA Q24246262-3E9C5FA4-80DB-4B5C-9A25-29D6B1CC1191 Q24597369-E872F16B-A17D-460D-AC82-96C12EAA1B6D Q24647794-29F81D37-37E1-4EE0-8DBB-32290C16C11A Q24683014-6CE3B29A-D446-45FA-B3F5-E26046EE3106 Q24683776-BDC0159D-7353-412A-A9D7-FBA31E90258B Q26770664-FD3DE3E8-08DD-4C82-B01B-AA0724217206 Q26770818-0583672E-B647-41AC-8828-C084FE319B32 Q26773978-BBBE746E-F9AF-4BF3-A3CC-78F80F29DB98 Q26776234-2402AF6D-6209-4F67-8BF0-744B1291BBBC Q26777329-CB3C93EF-5DBA-47A7-94C6-0BD8E4F8CBEF Q26777686-0EE1B9CF-0A4A-4B55-8AE6-8326D7A255A6 Q26779900-05C3FA32-84AB-4F9B-A6D5-776AFCA59DC9 Q26781389-FF88FBAA-FBD5-4BBC-99CB-9CC49FAD4173 Q26798434-AC6AEAE9-F49F-43E9-A959-371CA6CCCD11 Q26822611-A499D44D-9AD9-4029-A503-2E60C5B44189 Q26822941-BD1D5EFC-5831-4828-96FC-25F7EFD51333 Q26826930-A67F010D-8648-4C61-8387-7C4F91174C2B Q26828463-6E3DC4C2-D120-4E3E-B7E7-750EFC758862 Q26863227-F2C661A4-817A-40BF-9113-AA9AE8CFD4B9 Q26995437-70919B0F-25A5-4386-9994-D05090AEC9B2 Q26999417-BE272752-EF16-40A4-ACC5-022BB167D15D Q26999705-5D445A9D-89C9-4627-AD73-918F1D03E291 Q27000269-C406D7F9-2B2D-4EB2-9400-F89A2AFBA4D9 Q27004079-CC3E7268-B4B7-4334-A618-2D584E389000 Q27009769-E70EDEE9-A57A-438A-B2C6-367116BDB35E Q27021612-839DCC17-1292-4799-861F-34F77E96B395 Q27312315-5BD0630D-3D37-4F01-B3F8-F654ADD42C20 Q27319470-8DB153DE-6A9C-46B6-B006-1DB799F45AE4 Q27693249-89DC1BA1-2B2E-40B6-AE70-09D6A9D878C0 Q28066677-F2CC15D3-6E8D-4E7E-9E9E-DE6B34669AE9 Q28072906-92344934-A88F-404C-8220-D4429AAB6A03 Q28083872-43737401-DB5C-4CC8-AF7F-A9D43F64A34A Q28084633-13EC5C18-BE41-4117-A7B0-1466AB9A8C7A

P2860

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

http://www.wikidata.org/entity/Q44825022

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

@en

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

@nl

type

label

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

@en

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

@nl

prefLabel

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

@en

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

@nl

P1433

Q44825022-BC2E713F-B5D5-4E0B-9FC4-4CD0E1126C1C

P1476

Q44825022-9BD1F4BA-5D6E-4C8E-B012-648D2D42CE8E

P2093

Q44825022-2FC48746-84A7-414F-9BF0-71DC301E0973

Q44825022-34E171D3-52D9-4B7C-9AF9-06C6E2735316

Q44825022-3C30CA7C-3269-4458-B4DC-93C55F0730A7

Q44825022-43871F64-1771-451E-A519-5B35D2CC179A

Q44825022-4A8D0F7F-E92E-481F-9472-3166A4FE6522

Q44825022-4AB077B8-138E-4C75-AFAF-B3E18CBAF2B1

Q44825022-A471692C-9A90-4AFA-9B22-2AA46408E1A5

Q44825022-ACE4E2B7-9BB5-4486-8B1B-FAE353A0F59F

Q44825022-C6BE69B5-3693-41D5-AE5B-D4201EC1A434

Q44825022-D49F51A2-32DA-4776-A63E-F43BECF4487B

P304

Q44825022-1FB0CC2C-630E-4EC2-9C33-87F2F5C5B985

P31

Q44825022-28FFF296-6987-4D69-81B6-6EAA111BCB85

P356

Q44825022-FB76925B-9A56-4ABB-8132-93BC1D26ACE9

P407

Q44825022-B419E2D5-4F31-46B4-A6CC-CD0A43779574

P433

Q44825022-D3B7643F-0CB4-41A4-BD6E-3EAD8B551F77

P478

Q44825022-4674C2CB-968A-4C1B-A1DC-8361029FB175

P50

Q44825022-0EEB192F-7973-4F6A-9ADA-F68A4C43EF6A

Q44825022-C272B7F6-DF0B-4CD1-81B4-E2983DB34E9F

Q44825022-EE73C86F-6E9B-4676-B12F-EEABFB0DB273

P577

Q44825022-6517AAB9-1A09-46C8-B72F-1DFF782C7620

P5875

Q44825022-A4050FCC-E521-4323-AB3A-83C166F88114

P698

Q44825022-2457B7D7-E87A-47A0-A8DE-555C276592B7

P921

Q44825022-5648027E-8C87-4872-B04C-2F61DF30E220

P356

P1433

The New England Journal of Medicine

P1476

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

@en

P2093

Alfred W Sandrock

http://www.w3.org/2001/XMLSchema#string

Christian Confavreux

http://www.w3.org/2001/XMLSchema#string

Daniel R Wynn

http://www.w3.org/2001/XMLSchema#string

Ernst-Wilhelm Radue

http://www.w3.org/2001/XMLSchema#string

Frances Lynn

http://www.w3.org/2001/XMLSchema#string

Fred D Lublin

http://www.w3.org/2001/XMLSchema#string

Michael A Panzara

http://www.w3.org/2001/XMLSchema#string

Richard A Rudick

http://www.w3.org/2001/XMLSchema#string

SENTINEL Investigators

http://www.w3.org/2001/XMLSchema#string

William H Stuart

http://www.w3.org/2001/XMLSchema#string

P304

911-923

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA044396

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

354

http://www.w3.org/2001/XMLSchema#string

P50

Bianca Weinstock-Guttman

Peter A Calabresi

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7266639

http://www.w3.org/2001/XMLSchema#string

P698

16510745

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis